Adon Agro Commodities IPO GMP, Grey Market Premium Today – IPO Watch

Views: 74
0 0
Read Time:6 Minute, 58 Second


Q-Line Biotech Ltd. (QBL) is engaged within the enterprise of creating, manufacturing and advertising and marketing of various vary of reagents (together with kits and POC gadgets) & consumables and manufacturing, importing, distribution/provide of diagnostic gear for various diagnostic healthcare wants. The firm provides diagnostic gear and IVD merchandise for various diagnostic healthcare wants since 2013 instantly or by way of its distributor/s majorly to diagnostic service suppliers, hospitals and medical faculties. 

The firm has established its manufacturers over a interval of 12 years by way of its expertise, R & D, manufacturing capabilities and high quality assurance. The core segments of operations of the Company in IVD Industry embody Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments embody indigenous manufacturing of reagents together with Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology gear’s & gadgets. Further in the course of the Covid-19 pandemic, the corporate diversified its focus and with the technical collaboration of third-party institutes and thru its personal R&D group developed a spread of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits and so forth.

It is analysis pushed firm engaged in creating and manufacturing a variety of reagents formulations used throughout varied IVD and diagnostic wants. The firm leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /merchandise. Further, for its sure Class of Reagent & gear’s and gadgets manufacturing enterprise, the corporate has entered into technical collaboration with sure worldwide firms. Under the settlement phrases, it undertakes the manufacturing of those Reagent and gear’s and gadgets as per the technical collaboration and specs supplied by the companions or firms. 

With the assistance of those collaborations the gear and gadgets adhere to strict high quality management, worldwide requirements and certifications. As of March 31, 2026, the corporate employed 19 personnel at R&D laboratories, which constituted 5.25% of its complete everlasting worker energy. As of March 31, 2026, it had 362 workers on its payroll and extra 223 contract workers in varied departments.

Q-Line Biotech IPO

The firm is popping out with its maiden e-book constructing route IPO of 6253200 fairness shares of Rs. 10 every to mobilize Rs. 214.48 cr. on the higher cap. The firm has introduced a value band of Rs. 326 – Rs. 343 per share.  The minimal software to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and can shut on May 25, 2026. The IPO represent 26.81% of the post-IPO paid-up capital of the corporate. The shares might be listed on NSE SME Emerge. From the web proceeds of the IPO, it’s going to make the most of Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for compensation/prepayment of sure borrowings, and the remaining for basic company functions. 

The firm raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is collectively lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the problem. HEM group’s Hem Finlease Pvt. Ltd., is the market maker in addition to a syndicate member.

The firm has issued preliminary fairness capital at par worth. It raised additional fairness shares within the value vary of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has additionally issued bonus shares within the ratio of two for 1 in March 2016, and 9 for 1 in August 2025. The common value of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, firm’s present paid-up fairness capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the higher band of the IPO pricing, the corporate is searching for a market cap of Rs. 800.16 cr. 

On the monetary efficiency entrance, for the final three fiscals, the corporate has (on a consolidated foundation) posted complete earnings/ web revenue, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a web revenue of Rs. 38.69 cr. on a complete earnings of Rs. 236.50 cr. Though it posted development in its high strains for the reported durations, its backside line posted inconsistency. For FY25, it posted decrease web revenue of Rs. 28.13 cr., and for 9M-FY26, although the highest line is Rs, 236.50 cr. it posted bumper revenue of Rs. 38.69 cr. in a pre-IPO interval, that not solely increase eyebrows, but additionally concern over its sustainability going ahead. Despite greater different earnings for FY25, it marked decrease web following extra-ordinary merchandise of Rs. 16.97 cr. Its contingent legal responsibility stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its total borrowings of Rs. 242.57 cr. as of December 31, 2025, increase concern.

For the final two fiscals, the corporate has reported a mean EPS of Rs. 25.00, and a mean RoNW of 23.17%. The problem is priced at a P/BV of two.44 primarily based on its NAV of Rs. 140.81 per share as of December 31, 2025, however its post-IPO NAV knowledge is lacking from the provide paperwork.

If we attribute FY26 tremendous earnings to its post-IPO totally diluted paid-up fairness capital, then the asking value is at a P/E of 15.51, and primarily based on FY25 earnings, the P/E stands at 28.44. The problem seems totally priced, primarily based on its bumper earnings for 9M-FY26, which is probably not sustained. 

For the reported durations, the corporate has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of twenty-two.14%, 19.25%, 17.66%, 13.32%, respectively, for referred durations.

All quantities in Indian Rupees crores

The firm has not paid any dividends for the reported durations of the provide doc. It will undertake a prudent dividend coverage, primarily based on its monetary efficiency and future prospects. 

As per the provide doc, the corporate has no listed friends to match with.

The two service provider bankers related to this problem have dealt with 79 points up to now three years, out of which 8 points closed beneath the problem value on itemizing date.

QBL is engaged within the enterprise of creating, manufacturing and advertising and marketing of various vary of reagents and consumables. It posted development in its high strains for the reported durations, however suffered a setback for FY25 in backside line following accounting changes. As the corporate has no listed friends, it’s attempting to extract fancy value for its IPO. Based on its total monetary knowledge, the problem seems totally priced. Well-informed traders could park reasonable funds for long run.

Dilip Davda is a veteran monetary journalist related to the Indian inventory market since 1978. He has been contributing to print and digital media on capital markets, insurance coverage, and finance since 1985.

He is well known for reviewing public points and non-convertible debentures (NCDs) within the major market. Drawing on over three many years of market expertise and shut interplay with service provider bankers, his critiques concentrate on detailed basic and monetary evaluation of firms, with a particular emphasis on SME public points.

Disclaimer: The data supplied herein is solely for academic and informational functions and doesn’t represent a suggestion, solicitation, or advice to purchase or promote any securities. Readers are suggested to seek the advice of a certified monetary advisor earlier than making any funding choices. Investments within the securities market are topic to market dangers. The writer doesn’t intend to spend money on the securities mentioned.



Source link

#Adon #Agro #Commodities #IPO #GMP #Grey #Market #Premium #Today #IPO #Watch

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Social profiles